Blogs & Articles

GPI thought-leadership, pricing and market access insights. Our blogs, white papers and resources provide the latest strategic insight.

LATEST BLOGS / ARTICLES

FDA deals significant blow to low-priced Chinese oncology drugs

By GPI Global Pricing Innovations | 6 April 2022
FDA rejects application for sintilimab in combination with chemotherapy, to deal blow to Eli Lilly and creating additional challenges for low-priced Chinese oncology drugs in the US market.
Read more
All
  • All
  • Articles
  • Blogs
  • Research
Chinese oncology drugs

FDA deals significant blow to low-priced Chinese oncology drugs

6 April 2022
Female Scientist experimenting with a beaker in her hand

Women Scientists behind the COVID-19 vaccines

8 March 2022
Canada PMPRB

Canada’s PMPRB drug pricing reforms face additional legal challenges

24 February 2022
SDTR

Growing number of US states enacting legislation to lower drug prices

15 February 2022
NICE-Feature-Image

NICE’s latest reform – why was it needed and what does it mean for innovation?

28 January 2022
China Reimbursement

China issues 2021 national reimbursement drugs list, three key trends…

23 December 2021
Build-Back-Better-US-small

Build Back Better could set new precedent for US drug pricing controls

3 December 2021
GPI-Pulse-10-steps

10 steps for a successful market access strategy

20 September 2021